Montelukast in Parkinson Disease

StatusCompleted
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary completion date changed from estimate of Nov 20, 2026 to Aug 20, 2026
    • Eligibility criteria revised
    • Study site revised
  2. Primary completion date: Nov 20, 2024 to Nov 20, 2026
    • Study completion date: Dec 20, 2025 to Dec 20, 2026
    v6
  3. 3 versions Re-verified since Feb 23, 2024, no change to tracked fieldsv3-v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 7, 2023 to Nov 5, 2023
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mostafa Bahaa
14 trials monitored
See 1 trial at risk
Parkinson's Disease
1,462 trials monitored
See 71 trials at risk
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and/or rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS.
Trial Details
NCT Number NCT06113640
Lead Sponsor Mostafa Bahaa
Conditions
(from sponsor)		 Parkinson Disease
Related terms Parkinson Disease
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov